Our commitment is clear: to shift the paradigm on drug affordability while upholding the highest standards of quality, safety, and efficacy. In an environment where pricing and access remain key challenges, Biocon plays a pivotal role by providing high-quality biosimilars and generics to treat serious conditions like diabetes, cancer, obesity, and autoimmune diseases.

As the only company worldwide offering both biosimilar insulins and generic versions of complex peptides, particularly GLP-1s, Biocon is uniquely placed to address the expanding global “diabesity” opportunity through an integrated and scalable portfolio. In oncology, Biocon’s portfolio spans biosimilar monoclonal antibodies and oncology-focused generic Highly Potent Active Pharmaceutical Ingredients (HPAPIs) and formulations enables the company to accelerate global access to affordable cancer therapies and strengthen its leadership in this high-value segment.